Literature DB >> 21949923

The challenges of renal replacement therapy and renal palliative care in the elderly.

C Isles1, S Robertson, A Almond, K Donaldson, D Clark.   

Abstract

The main aim of this review is to let general practitioners and physicians understand what happens to older patients after referral to the renal service. Usually, most patients will be managed completely by the renal team, either because the patient requires dialysis or because conservative but specialised care is appropriate. The recent increase in dialysis rate can mostly be accounted for by older patients for whom such demanding treatment was previously thought to be contraindicated. The decision to dialyse the elderly still remains difficult, with recent data suggesting that if there are significant comorbidities the survival advantage of dialysis in patients over 75 years of age is unlikely to be more than four months. Towards the end of life, conservative treatment is not simply a decision not to dialyse, but comprises active disease management, including treatment of anaemia and other supportive care, which may become increasingly complex, e.g. pain relief with fentanyl and alfentanyl. Older patients who decide to accept dialysis treatment contend with all the usual end of life issues of older people. They have an additional option, denied to the rest of us, of dialysis withdrawal; this effectively allows them to die at a time of their choosing.

Entities:  

Mesh:

Year:  2011        PMID: 21949923     DOI: 10.4997/JRCPE.2011.313

Source DB:  PubMed          Journal:  J R Coll Physicians Edinb        ISSN: 1478-2715


  2 in total

1.  "Should I go on dialysis, Doc?": initiating dialysis in elderly patients with end-stage renal disease.

Authors:  Dori Seccareccia; James Downar
Journal:  Can Fam Physician       Date:  2012-12       Impact factor: 3.275

2.  Supportive Care: Comprehensive Conservative Care in End-Stage Kidney Disease.

Authors:  Fliss E M Murtagh; Aine Burns; Olivier Moranne; Rachael L Morton; Saraladevi Naicker
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-10       Impact factor: 8.237

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.